Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Receivables (2020 - 2025)

Tarsus Pharmaceuticals has reported Receivables over the past 6 years, most recently at $87.1 million for Q4 2025.

  • Quarterly results put Receivables at $87.1 million for Q4 2025, up 81.25% from a year ago — trailing twelve months through Dec 2025 was $87.1 million (up 81.25% YoY), and the annual figure for FY2025 was $87.1 million, up 81.25%.
  • Receivables for Q4 2025 was $87.1 million at Tarsus Pharmaceuticals, up from $74.3 million in the prior quarter.
  • Over the last five years, Receivables for TARS hit a ceiling of $87.1 million in Q4 2025 and a floor of $200000.0 in Q4 2021.
  • Median Receivables over the past 5 years was $25.2 million (2021), compared with a mean of $28.6 million.
  • Peak annual rise in Receivables hit 1691.0% in 2022, while the deepest fall reached 99.0% in 2022.
  • Tarsus Pharmaceuticals' Receivables stood at $200000.0 in 2021, then skyrocketed by 1691.0% to $3.6 million in 2022, then skyrocketed by 394.53% to $17.7 million in 2023, then soared by 171.31% to $48.1 million in 2024, then skyrocketed by 81.25% to $87.1 million in 2025.
  • The last three reported values for Receivables were $87.1 million (Q4 2025), $74.3 million (Q3 2025), and $60.2 million (Q2 2025) per Business Quant data.